Investors' efforts to maintain the P/S amidst a steady reven...
Investors' efforts to maintain the P/S amidst a steady revenue decline seems questionable and unsustainable. The company's potential overvaluation due to the grim revenue prospect hints at investors possibly paying more for the stock.
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Shares May Have Run Too Fast Too Soon
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment